ilaris


  • Product Code: ilaris
  • Ilaris (canakinumab) is a fully human IgG1 monoclonal antibody designed to bind selectively to IL‑1β and block its interaction with IL‑1 receptors, thereby dampening inflammatory pathways driven by this cytokine Administered as a subcutaneous injection (typically 150 mg or weight-based dosing), it has a half-life of approximately 26 days with peak blood concentrations reached around one week post-injection

    Approved Uses Include:

    • Cryopyrin-Associated Periodic Syndromes (CAPS): Muckle-Wells syndrome, Neonatal-Onset Multisystem Inflammatory Disease (NOMID/CINCA), familial cold urticaria

    • Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)

    • Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)

    • Familial Mediterranean Fever (FMF)

    • Still’s Disease: Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged ≥ 2 years

    • Gout Flares: For adults with frequent attacks who do not respond to or cannot tolerate NSAIDs, colchicine, or steroids

    Mechanism & Benefits:
    Ilaris intercepts IL‑1β, a key inflammatory mediator, reducing symptoms like fever, joint pain, rashes, fatigue, and systemic inflammation. Clinical trials show rapid improvement—typically within 7 days—with over 70% of CAPS patients responding fully by this time and 97% by eight weeks

    Administration & Safety Profile:

    • Given under the skin by a healthcare provider every 4–8 weeks, depending on indication

    • Common side effects include upper respiratory infections, injection-site reactions, headache, nausea, abdominal pain, and sometimes vertigo 

    • Serious risks include increased susceptibility to infections (including TB) and rare hypersensitivity events. Live vaccines are contraindicated during treatment, and TB screening is required before starting therapy

    Pharmacokinetics & Efficacy Monitoring:

    • Peak serum levels occur ~7 days post-dose; half‑life ~26 days; bioavailability ~66%

    • Biomarkers like C‑reactive protein (CRP) and Serum Amyloid A (SAA) typically normalise within days of treatment

  • Availability: In Stock

Available Options


Important Note: We can only ship a maximum 90-day supply of your prescription. If in doubt, please call before placing your order.